Davita Healthcare Partners stock hits 52-week low at $122.91

DaVita HealthCare Partners stock reached a 52-week low, touching $122.91, marking a significant point for investors and analysts alike. Over the past year, the company's stock has experienced a decline, with a 1-year total return of -10.38% and a steeper YTD decline of -15.37%. Despite these challenges, InvestingPro data reveals management has been aggressively buying back shares, and the company maintains a healthy P/E ratio of 12.68 with an attractive 14% free cash flow yield. This downturn reflects challenges the company may be facing in the current market environment, though DaVita's overall financial health score remains "GREAT" according to InvestingPro analysis. The current price appears slightly undervalued compared to its Fair Value. The new low underscores the volatility and pressure within the healthcare sector, prompting stakeholders to reassess their strategies and outlooks for the coming months. Investors seeking deeper insights can access DaVita's comprehensive Pro Research Report, one of 1,400+ available exclusively on InvestingPro.

In other recent news, DaVita HealthCare Partners Inc reported its third-quarter 2025 earnings, showing results that fell short of expectations. The company announced an earnings per share (EPS) of $2.51, which was significantly below the anticipated $3.23, resulting in a 22.29% negative surprise. Additionally, DaVita's revenue was reported at $3.42 billion, slightly missing the forecasted $3.44 billion. These financial results highlight a challenging quarter for DaVita, with both earnings and revenue not meeting analyst projections. There were no updates regarding mergers or acquisitions. Analyst firms have not publicly issued any recent upgrades or downgrades for DaVita following these earnings results. This information reflects the latest developments concerning DaVita's financial performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.